QIAGEN leverages QuantiFERON®-TB technology to advance global efforts against TB TB IGRA testing now accessible in high burden, low resource and decentralized settings Study data also showcased at the ...
QuantiFERON franchise benefits from new applications, products and automation options, building on strengths in tuberculosis detection while addressing new disease targets QuantiFERON SARS-CoV-2 assay ...
QIAGEN’s New Generation of QuantiFERON TB Test Gains Chinese Approval and Renewed WHO Recommendation
HILDEN, Germany & GERMANTOWN, Md. & SHANGHAI--(BUSINESS WIRE)--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that its QuantiFERON tuberculosis (TB) testing solution has ...
Venlo, the Netherlands, June 15, 2023 (GLOBE NEWSWIRE) -- QIAGEN (QGEN) (NYSE: QGEN; Frankfurt Prime Standard: QIA) welcomes the publication of a new, systematic review highlighting the unique value ...
QIAGEN QGEN recently reached a major landmark in the field of tuberculosis (TB) testing. On World TB Day, the company announced that since the lime of its launch, the company’s QuantiFERON blood test ...
Data on performance of QuantiFERON-TB Gold In-Tube test (QFT) and tuberculin skin test (TST) in children with active tuberculosis from high burden countries in the context of micronutrient deficiency ...
HILDEN, Germany & GERMANTOWN, Md.--(BUSINESS WIRE)--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the launch and CE marking of QIAreach® QuantiFERON®-TB test for tuberculosis ...
QuantiFERON-TB Gold Plus is the world’s leading IGRA blood test, with millions of tests performed annually. It has established itself as a superior alternative to the dated TB skin test (TST), which ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback